Wealth Alliance Sells 13 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wealth Alliance decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 571 shares of the biopharmaceutical company’s stock after selling 13 shares during the period. Wealth Alliance’s holdings in Regeneron Pharmaceuticals were worth $600,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after buying an additional 91,956 shares during the period. Capital World Investors lifted its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the last quarter. Capital International Investors lifted its stake in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Putnam Investments LLC lifted its stake in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:REGN opened at $1,138.81 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The stock’s 50-day moving average is $1,129.45 and its 200 day moving average is $1,029.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The company has a market cap of $125.48 billion, a PE ratio of 33.64, a P/E/G ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the business earned $8.79 EPS. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,026 shares of company stock worth $11,498,705. Company insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on REGN shares. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Piper Sandler lifted their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Finally, Truist Financial reiterated a “buy” rating and issued a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.